MedTrace Logo

Efficacy and Safety of Surinabant Treatment as an Aid to Smoking Cessation (SURSMOKE)

NCT00432575 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 810

Last updated 2009-04-15

No results posted yet for this study

Summary

Surinabant is a new, potent and selective antagonist for the cannabinoid CB1 receptor, which might be clinically useful in the treatment of dependence to nicotine.

The primary study objective is the assessment of efficacy of 3 doses of surinabant on abstinence from smoking in cigarette smokers. The main secondary objectives are the effect of surinabant on body weight and its clinical and biological safety.

Conditions

  • Smoking Cessation

Interventions

DRUG

surinabant (SR147778)

oral administration

DRUG

placebo

oral administration

Sponsors & Collaborators

Principal Investigators

  • Claire VILAIN, M.D. · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • Belgium
  • France
  • Germany
  • Italy
  • Norway
  • Spain
  • Sweden
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00432575 on ClinicalTrials.gov